19 studies found for:    alpharadin | Open Studies
Show Display Options
Rank Status Study
1 Recruiting BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
Condition: Non Small Cell Lung Cancer With Bone Metastatses
Intervention: Biological: Xofigo
2 Not yet recruiting Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
Condition: Prostatic Neoplasms, Castration-Resistant
Intervention: Drug: Radium-223 dichloride (Xofigo, BAY 88-8223)
3 Recruiting Phase II Trial of Ra-223 Dichloride and Hormonal Treatment
Condition: Breast Cancer
Interventions: Drug: Ra-223 dichloride;   Drug: Denosumab;   Drug: Hormone Therapy
4 Recruiting Radium 223 Following Intermittent ADT
Condition: Prostate Cancer
Intervention: Radiation: Radium 223 Dichloride (Xofigo®)
5 Recruiting Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases
Condition: Castration-Resistant Prostatic Cancer
Intervention: Drug: Radium-223 dichloride, (Xofigo, BAY88-8223)
6 Recruiting Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany
Condition: Prostatic Neoplasms, Castration-Resistant
Intervention: Drug: Radium-223-dichloride (Xofigo, BAY88-8223)
7 Recruiting Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer
Condition: Thyroid Cancer
Intervention: Radiation: Radium 223
8 Recruiting Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)
Condition: Prostate Carcinoma
Interventions: Drug: Radium-223 dichloride;   Other: Conventional or high dose radiotherapy
9 Not yet recruiting Treatment Patterns in Metastatic Prostate Cancer
Condition: Prostatic Neoplasm
Intervention: Drug: Xofigo (Radium 223 dichloride,BAY88-8223)
10 Recruiting Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Pazopanib;   Drug: Sorafenib;   Drug: Radium-223
11 Recruiting NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Prostate Carcinoma
Interventions: Procedure: Contrast-enhanced Magnetic Resonance Imaging;   Radiation: Fludeoxyglucose F-18;   Radiation: Fluorine F 18 Sodium Fluoride;   Procedure: Magnetic Resonance Imaging;   Procedure: Positron Emission Tomography
12 Recruiting Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
Condition: Prostate Cancer
Interventions: Drug: Radium-223;   Biological: Sipuleucel-T
13 Not yet recruiting Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223);   Drug: Placebo;   Drug: Bortezomib;   Drug: Dexamethasone
14 Recruiting Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223);   Drug: Placebo (saline);   Other: Background hormonal therapy
15 Recruiting Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223);   Drug: Placebo (saline);   Drug: Exemestane;   Drug: Everolimus
16 Recruiting Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
17 Recruiting Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
Condition: Prostatic Neoplasms
Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223);   Drug: Matching placebo (normal saline);   Drug: Abiraterone;   Drug: Prednisone/Prednisolone
18 Recruiting Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis
Condition: Prostate Carcinoma Metastatic to the Bone
Interventions: Drug: Enzalutamide;   Radiation: Radium ra 223 dichloride
19 Recruiting Radium-223 Dichloride Long-term Follow-up Program
Condition: Neoplasm Metastasis / Bone and Bones
Intervention: Other: Data Collection

Indicates status has not been verified in more than two years